tradingkey.logo

Vir Biotechnology Inc <VIR.OQ> expected to post a loss of 84 cents a share - Earnings Preview

ReutersMay 5, 2025 9:57 PM
  • Vir Biotechnology Inc VIR.OQ VIR.O is expected to show a fall in quarterly revenue when it reports results on May 7 for the period ending March 31 2025

  • The San Francisco California-based company is expected to report a 84.8% decrease in revenue to $8.592 million from $56.38 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Vir Biotechnology Inc is for a loss of 84 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Vir Biotechnology Inc is $20.00​, above​ its last closing price of $6.16. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.87

-0.87

-0.76

Beat

12.9

Sep. 30 2024

-1.07

-1.05

-1.56

Missed

-48.2

Jun. 30 2024

-0.88

-0.90

-1.02

Missed

-13.9​

Mar. 31 2024

-1.06

-1.05

-0.48

Beat

54.3

​​Dec. 31 2023

-1.11

-1.01

-0.86

Beat

14.7

Sep. 30 2023

-1.25

-1.21

-1.22

Missed

-1.2​

Jun. 30 2023

-1.19

-1.20

-1.45

Missed

-20.5

Mar. 31 2023

-0.74

-0.87

-1.06

Missed

-21.2

This summary was machine generated May 5 at 21:57 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI